The Access Consortium — comprising regulatory
authorities from the UK, Australia,
Canada, Singapore and Switzerland — works together to
streamline regulatory processes, support innovation and improve
global public health outcomes.
The Medicines and Healthcare products Regulatory Agency (MHRA)
has formally begun its year as chair of the Access
Consortium for 2026, marking a new phase of international
regulatory collaboration aimed at strengthening patient access to
safe, effective medicines.
The Access Consortium — comprising regulatory
authorities from the UK, Australia,
Canada, Singapore and Switzerland — works together to
streamline regulatory processes, support innovation and improve
global public health outcomes.
Lawrence Tallon, MHRA Chief Executive, said the Agency is
committed to advancing the Consortium's reputation as a trusted,
forward-looking network.
“On behalf of the medicines regulatory agencies in the
UK, Canada, Australia and Singapore, I would like to
thank our colleagues at SwissMedic for expertly
chairing Access in 2025. 2026 will be an important year for
the Consortium in which we jointly drive forward the
delivery of our exciting GROWTH manifesto. We
will build on our strong foundations and deliver
real benefits for patients and industry across our five
partner countries and the global community,” he said.
For more information visit the Access Consortium Website.
